Piper Sandler raised the firm’s price target on Xeris Biopharma (XERS) to $4 from $3 and keeps a Neutral rating on the shares. The firm notes Xeris reported a Q4 net loss per share of (3c) on total revenues of $60.1M, compared to Street estimates of (6c) and $58.1M, respectively. Management is guiding to 2025 total revenue of $255M-$275M, implying annual growth of about 35% versus 2024 at the midpoint.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XERS:
- Xeris Pharmaceuticals: Strong Growth Potential and Financial Stability Justify Buy Rating
- Xeris Biopharma price target raised to $8 from $6.60 at H.C. Wainwright
- Xeris Biopharma Reports Record Revenue and Strong 2025 Outlook
- Xeris Biopharma files $250M mixed securities shelf
- Xeris Biopharma reports Q4 EPS (3c), consensus (2c)